Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock Holdings Raised by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP increased its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 32.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 345,000 shares of the company's stock after acquiring an additional 85,000 shares during the period. Hudson Bay Capital Management LP owned approximately 0.28% of Apellis Pharmaceuticals worth $11,009,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of APLS. Boxer Capital Management LLC purchased a new stake in Apellis Pharmaceuticals during the fourth quarter worth about $45,504,000. National Bank of Canada FI lifted its position in shares of Apellis Pharmaceuticals by 266,361.5% during the 4th quarter. National Bank of Canada FI now owns 1,385,600 shares of the company's stock valued at $44,214,000 after acquiring an additional 1,385,080 shares during the period. Cibc World Markets Corp purchased a new stake in shares of Apellis Pharmaceuticals during the 4th quarter worth approximately $41,014,000. Avoro Capital Advisors LLC grew its holdings in shares of Apellis Pharmaceuticals by 10.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company's stock worth $390,011,000 after acquiring an additional 1,111,111 shares during the period. Finally, Norges Bank purchased a new position in Apellis Pharmaceuticals in the 4th quarter valued at approximately $34,662,000. Hedge funds and other institutional investors own 96.29% of the company's stock.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the transaction, the general counsel now directly owns 138,730 shares of the company's stock, valued at $3,482,123. This represents a 3.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 6.50% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Trading Down 2.0%

APLS traded down $0.34 during trading on Thursday, hitting $16.36. 2,545,604 shares of the company's stock were exchanged, compared to its average volume of 2,229,767. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.11 and a 1 year high of $43.99. The stock has a 50 day moving average price of $20.66 and a 200 day moving average price of $26.85. The firm has a market cap of $2.06 billion, a P/E ratio of -8.06 and a beta of 0.73. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same period last year, the business earned ($0.54) EPS. The firm's revenue was down 3.2% compared to the same quarter last year. As a group, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on APLS shares. Cantor Fitzgerald assumed coverage on Apellis Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $44.00 target price on the stock. Bank of America downgraded shares of Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their target price for the company from $41.00 to $23.00 in a report on Friday, May 9th. Royal Bank of Canada reduced their target price on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating on the stock in a research note on Thursday, May 8th. Wells Fargo & Company dropped their price objective on Apellis Pharmaceuticals from $30.00 to $26.00 and set an "equal weight" rating for the company in a research report on Thursday, May 8th. Finally, Robert W. Baird decreased their price target on shares of Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. Nine investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $40.42.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).